The Clinical Efficacy Of Nimotuzumab Combined With Chemotherapy In Treatment Of Advanced Pancreatic Cancer

Background and ObjectivePancreatic cancer is one of the malignant digestive system tumors with higher levels.Surgical excision might be a good treatment choice and offer hope for long-term survival for early pancreatic cancer.However,early pancreatic cancer is rarely discovered,and most patients are diagnosed at the advanced stage.Therefore,the treatment is mainly palliative care.The clinical efficacy of traditional radiotherapy or chemotherapy is limited,even accompanied by serious side effects.The living quality of patients decreased significantly.Therefore,to explore more effective and less side effects of treatment is imperative.With the deep understanding of the biological characteristic of pancreatic cancer,the study found that there is a multi-gene mutation in pancreatic cancer,and it provides a variety of possible targets for the therapy of pancreatic cancer.Compared with cytotoxic drugs,targeted drugs have a better effect and less adverse effects.The aim of this study was to investigate the clinical efficacy of nimotuzumab combined with chemotherapy in advanced pancreatic cancer patients.Methods and patients1.Retrospectively analyzed the clinical data of 34 cases with advanced pancreatic cancer diagnosed by the First Affiliated Hospital of Da Lian Medical University,Da Lian City Central Hospital and Chinese People's Liberation Army 210 Hospital in 2013.01-2016.01.According to the treatment,patients were divided into two groups:observation group which included 14 cases was treated with nimotuzumab combined with gemcitabine(GEM)and tiggio(S-1),or nimotuzumab combined with gemcitabine,compared with 20 cases of gemcitabine and tiggio chemotherapy,or gemcitabine(control group)in advanced pancreatic cancer during the same period.The aim of this study was to compare of the two groups of clinical benefit response,recent efficacy,clinical benefit response,survival time and toxic side effects.2.All dates were analyzed by the software SPSS 17.0.The count data was described by rate and percentage,the comparison of the count data used by Fisher's exact probability test,the measurement data used t test,if the variance is not using t'test(if for non-normal distribution,using Wilcoxon rank and inspection),and the grade data used rank sum.The Kaplan-Meier and Log-Rank methods were used for testing and survival analysis.According to ? = 0.05 for the test level,P values less than 0.05 were considered statistically significant.Results1.The clinical benefit response was significantly higher in the observation group than in the control group:the rate of pain relief,physical condition improvement and weight gain were 78.6%vsl5%,64.3%vs10%,42.9%vs10%,the difference was statistically significant(P<0.05);2.The overall response rate of the observation group and the control group was no significant difference(28.6%vs5%,P>0.05),while the control rate of disease was 85.7%vs30%,the difference was statistically significant(P<0.05);the incidence of tumor markers including carcino-embryonic antigen(CEA)and carbohydrate antigen 19-9(CA19-9)decreased was 64.3%vs25%,the difference was statistically significant(P<0.05);3.The median overall survival was 10.9 months vs6.9 months,and the difference was statistically significant(P<0.05),The 1-year survival rates were 35.7%(5/14)and 10%(2/20)respectively,the difference was no significant(P>0.05);4.The toxicity mainly manifested as myelosuppression,gastrointestinal reactions,liver and kidney injury,and the whole group had no patients with grade ? toxicity.The incidence of leukopenia,neutropenia,thrombocytopenia,anemia was 42.86%vs60%,50.00%vs80%,14.29%vs45%,21.43%vs50%in blood toxicity,and the difference was not statistically significant(P>0.05).The incidence of gastrointestinal reactions in the observation group and the control group was 71.43%and80%,respectively.There was no significant difference between the two groups(P>0.05).The incidence of liver and kidney injury in the observation group and the control group was 21.43%and40%respectively.There was no significant difference between the two groups(P>0.05).These data suggested that the addition of nimotuzumab did not increase the incidence rate of adverse reactions in patients with chemotherapy.ConclusionsThe treatment of patients with advanced pancreatic cancer with nimotuzumab combined with chemotherapy can bring significant clinical benefit response and improve the short-term curative effect without increasing the incidence of adverse reactions with less impaction on the quality of life for patients.In the treatment of advanced pancreatic cancer patients,the efficacy and safety of nimotuzumab is worthy of recognition.Therefore,the nimotuzumab might be one of the effective choice of patients with advanced pancreatic cancer.